CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

These companies could innovate their way to success.

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up roughly 3.8% of ARK Investment’s disclosed equity portfolio at ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

CRISPR Therapeutics AG (CRSP) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...